Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: A pilot study☆
References (67)
- et al.
Central biogenic amine metabolism in children with the syndrome of chronic multiple tics of Gilles de la Tourette syndrome: Norepinephine, serotonin, and dopamine
Journal of the American Academy of Child Psychiatry
(1979) - et al.
Tourette syndrome and the opioid system
Psychiatry Research
(1985) Mu receptor-serotonin link in opioid induced hyperactivity in mice
Life Sciences
(1990)- et al.
Gilles de la Tourette's syndrome: A postmortem neuropathological and immunohistochemical study
Journal of Neurological Science
(1986) - et al.
Enkephalin, dynorphin, and substance P in postmortem substantia nigra from normals and schizophrenic patients
Life Sciences
(1991) Behavioral effects of dynorphin: A novel opioid neuropeptide
Neuropharmacology
(1980)- et al.
Reduction in opioid and non-opioid forms of swim analgesia by 5-HT2 receptor antagonists
Brain Research
(1989) - et al.
Growth hormone response to clonidine in children ages 4–17: Tourette's syndrome vs. children with short stature
Journal of the American Academy of Child Psychiatry
(1984) - et al.
Basal ganglia research and Tourette's syndrome
Trends in Neuroscience
(1991) - et al.
Elevated CSF dynorphin A[1–8] in Tourette's syndrome
Life Sciences
(1988)
The Yale Global Tic Severity Scale: Initial testing of a clinician-rated scale of tic severity
Journal of the American Academy of Child and Adolescent Psychiatry
Regulation of the concentration of dynorphin A[1–8] in the striatonigral pathway by the dopaminergic system
Brain Research
Anatomy of CNS opioid receptors
Trends in Neuroscience
Dopamine-independent motor behavior following microinjection of rimorphin in the substantia nigra
Brain Research
Opiate receptor binding sites in human brain
Brain Research
Possible interactions between dynorphin and dopaminergic systems in rat basal ganglia and substantia nigra
Brain Research
Opioid peptides in Huntington's disease: Alterations in prodynorphin and proenkephalin systems
Brain Research
Dual opioid modulation of the action potential duration of mouse dorsal root ganglion neurons in culture
Brain Research
Dynorphin levels in parkinsonian patients: Leu-enkephalin production from iether proenkephalin A or prodynorphin in human brain
Brain Research
Opposite effects of mu and k opiates on the firing rate of dopamine cells in the substantia nigra of the rat
European Journal of Pharmacology
Opioid receptor regulation of the release of norepinephrine in brain
Neuropharmacology
Alpha2-adrenergic, kappa-opiate, and P1-purinergic autoreceptors have mutually antagonistic effects: A new regulatory mechanism?
Journal of Neurochemistry
Presynaptic kappa-opioid receptors on noradrenergic nerve terminals couple to G proteins and interact with the alpha2-adrenoceptors
Journal of Neurochemistry
DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders
Effects of naloxone and naltrexone on self-injury: A double-blind, placebo-controlled analysis
American Journal of Mental Retardation
Opiate therapy and self-harming behavior in Tourette's syndrome
Movement Disorders
Biochemical and genetic studies of Tourette's syndrome
Neuroendocrine and behavioral effects of naloxone in Tourette's syndrome
Dynorphin is a specific endogenous ligand of the K opioid receptor
Science
Kappa opiate receptor multiplicity: Evidence for two U50,488-sensitive kappa1 subtypes and a novel kappa3 subtypes
Journal of Pharmacology and Experimental Therapeutics
Chronic, multiple tics of Gilles de la Tourette's disease: CSF acid monoamine metabolites after probenecid administration
Archives of General Psychiatry
Dynorphin-related peptides cause motor dysfunction in the rat through a non-opiate action
British Journal of Pharmacology
Dynorphin effects on plasma concentrations of anterior pituitary hormones in the nonhuman primate
Journal of Pharmacology and Experimental Therapeutics
Cited by (44)
Nalmefene, a mu opioid receptor antagonist/kappa opioid receptor partial agonist, potentiates cocaine motivation but not intake with extended access self-administration in adult male mice
2021, NeuropharmacologyCitation Excerpt :The kappa opioid receptor (KOR) may be a viable target for CUD given the counter modulatory effect of KOR activation on dopamine release (Devine et al., 1993) and ability to block cocaine evoked dopamine overflow in the striatum (Zhang et al., 2004a, b). However, centrally acting KOR full agonists have been shown to have aversive effects in rodents and humans (Bart et al., 2005; Chappell et al., 1993; Pfeiffer et al., 1986). Therefore, a KOR partial agonist that is able to block cocaine reward without the aversive effects observed with full agonists may be a more viable pharmacotherapeutic for CUD (Kreek et al., 2002).
Tourette disorder and other tic disorders
2019, Handbook of Clinical NeurologyCitation Excerpt :Identifying the most troublesome, focal, and typically simple tics is important prior to the use of BoNT (Thenganatt and Jankovic, 2016). Multiple additional agents have been studied for possible efficacy in TS, including glutamatergic agents, d-serine, riluzole (Lemmon et al., 2015), and N-acetylcysteine (Bloch et al., 2016a), nicotinic agents nicotine (McConville et al., 1992; Silver et al., 2001b; Howson et al., 2004), mecamylamine (Silver et al., 2001a), metoclopraminde (Nicolson et al., 2005), ondansetron (Toren et al., 2005), lithium (Kerbeshian and Burd, 1988), dopamine agonists, such as pramipexole (Kurlan et al., 2012) and talipexole (Goetz et al., 1994), naloxone (van Wattum et al., 2000), buspirone (Dursun et al., 1995), SSRIs (Scahill et al., 1997), vigabatrin (Catalyst Pharmaceutical Partners Inc., 2015), omega-3 fatty acid (Gabbay et al., 2012), physostigmine (Stahl and Berger, 1980), and spiradoline mesylate (Chappell et al., 1993). Some of these are based on hypotheses of the mechanism of TS development and treatment, e.g., glutamatergic agents (Lemmon et al., 2015); some have been effective in related disorders, e.g., SSRIs (Scahill et al., 1997); and some have been tried for other reasons.
Tourette Syndrome and Tic Disorders
2016, Handbook of Behavioral NeuroscienceCitation Excerpt :TS symptoms have been exacerbated upon removal of chronic opiate treatment (Lichter et al., 1988). The use of a specific kappa receptor agonist, spiradoline, improved tics at a low dose, but had a paradoxical worsening at higher dose (Chappell et al., 1993). Studies evaluating opiate antagonists have also produced some conflicting results.
Psychiatric neural networks and neuropharmacology: Selected advances and novel implications
2014, Saudi Pharmaceutical JournalCitation Excerpt :Importantly, it is admitted that all addictive drugs promote DA function (Di Chiara and Imperato, 1988; Wise and Bozarth, 1987) and buprenorphine, which is an opioid with an ability to disrupt KOR function, has been described with antidepressant effects (Bodkin et al., 1995) which link more KOR function to depression, moreover, this concept has been further fueled by findings. Indeed, KOR agonists, like spiradoline and enadoline, were pointed as a possible medication for mood disorders and, while spiradoline can reduce tics frequency and provoke sedation in patients with Tourette’s Syndrome (Chappell et al., 1993), enadoline can produce sedation, depersonalization, visual distortions, confusion and paranoia (Walsh et al., 2001a,b). On the other hand salvinorin A was also described with antidepressant effects (Carlezon et al., 2009).
Use patterns and self-reported effects of Salvia divinorum: An internet-based survey
2010, Drug and Alcohol DependenceCitation Excerpt :Given that we did not ask participants detailed questions about their experiences with other drugs or for specific comparisons between SD and other drugs, we are limited in our ability to characterize the subjective effects of SD. Nonetheless, the reported effects of SD in our sample are generally consistent with KOR agonists’ known clinical effects, such as sedation, difficulty concentrating (Ashton et al., 1989; Chappell et al., 1993; Kramer et al., 2000; Martin et al., 1965; Pfeiffer et al., 1986; Reece et al., 1994; Rimoy et al., 1994; Walsh et al., 2001), auditory and visual distortions, and feelings of depersonalization (Chappell et al., 1993). In addition to the hallucinogen-like effects, Gonzalez et al. (2006) noted that 44% of their 32 participants reported experiencing some degree of adverse symptoms immediately after the acute effects of SD.
Kappa-opioid ligands in the study and treatment of mood disorders
2009, Pharmacology and Therapeutics
- ☆
A portion of this study was presented at the Annual Meeting of the American College of Neuropsychopharmacology, San Juan, PR, December 16, 1989.